Manchin Chang, MD
Endocrinology, Diabetes & Metabolism · Providence, RINPI 1346442563
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Amgen at 44.5% of the total. 2025 is the largest year on record at $427, 3.2 times the $134 reported in 2019.
Across 26 payments — averaging $33.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$391
- Corcept Therapeutics$125
- Radius Health, Inc.$121
- AbbVie$121
- Amneal Pharmaceuticals LLC$31
- Lilly USA, LLC$22
- plus $67 from 4 others
What the payments were for
- Food & beverage$86699%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 11 | $391 |
| Corcept Therapeutics | 1 | $125 |
| Radius Health, Inc. | 1 | $121 |
| AbbVie | 7 | $121 |
| Amneal Pharmaceuticals LLC | 1 | $31 |
| Lilly USA, LLC | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$878 in reported general payments places this provider in the 65th percentile of 30 endocrinology, diabetes & metabolism providers in Rhode Island.
See all endocrinology, diabetes & metabolism providers in Rhode Island →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 819 | $721,598 |
| OzempicSemaglutide | 529 | $651,592 |
| TrulicityDulaglutide | 291 | $375,835 |
| MounjaroTirzepatide | 129 | $164,872 |
| JanuviaSitagliptin Phosphate | 132 | $115,649 |
| Tresiba Flextouch U-200Insulin Degludec | 97 | $109,672 |
| RybelsusSemaglutide | 99 | $109,417 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 134 | $102,102 |
| TradjentaLinagliptin | 152 | $96,960 |
| FarxigaDapagliflozin Propanediol | 119 | $84,408 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 95 | $68,065 |
| ProliaDenosumab | 38 | $65,388 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $64,554 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 352 | $59,375 |
| Humalog Kwikpen U-100Insulin Lispro | 176 | $51,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humalog Mix 75-25, Humulin 70-30 | $22 | $585,849569 claims |
| AmgenProlia | $391 | $65,38838 claims |
| AbbVieSynthroid | $121 | $34,915457 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $15 | $28,88481 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $31 | $17,6511,696 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 30 endocrinology, diabetes & metabolism providers in Rhode Island.
Other endocrinology, diabetes & metabolism in Providence
- Robert DobrzynskiProvidence$245K
- Robert SmithProvidence$80K
- Joseph TucciProvidence$30K
- Roberto OrtizProvidence$598
- Daryl SelenProvidence$450
- Alicia WarnockProvidence$317
- Meghana KoletiProvidence$145
- Charles KahnProvidence$125
- David MacleanProvidence$121
- Frank D'alessandroNorth Providence$193K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.